The contrast is hard to ignore: A test can be used to fire someone or support a criminal case, yet it remains unavailable to the physician in an emergency room trying to save that person’s life, when minutes are essential.
Tests used in patient care must meet FDA requirements for clinical diagnostics. Point-of-care testing—testing performed at or near the bedside—also requires an additional determination that the test is simple and low-risk enough to qualify for waived status under the Clinical Laboratory Improvement Amendments (CLIA). There is a legitimate reason for that regulatory distinction. Tests used to make medical decisions should be accurate, reliable, and interpreted appropriately. A rapid screen is not definitive toxicology, and it should not be treated as such.
Starting in 2020, xylazine spread through the fentanyl supply, introducing a new clinical hurdle: naloxone reverses opioids, but not xylazine. Patients can remain dangerously sedated or unstable even after naloxone is given. Further, xylazine is associated with necrotic skin wounds that increase risk of sepsis, and withdrawal syndromes that are more complex to treat than opioids alone.
There are no point-of-care tests for either of these drugs or other alarming and novel chemicals like cychlorphine, an opioid that does not show up on fentanyl tests. Because of that, clinicians have to follow information from law-enforcement seizures, public-health alerts, and months-old fatality data rather than from tests at the bedside. These data are in siloes and not easy to access or combine.
The FDA should establish an expedited pathway for clinical tests targeting emerging drug threats, triggered when agencies such as the U.S. Centers for Disease Control and Prevention (CDC) or the Office of National Drug Control Policy identify a substance of significant and growing public-health concern. The agency already has a dual pathway through which manufacturers can seek a special clearance and a CLIA waiver together. That framework could be prioritized and adapted for emerging drugs rather than forcing each new threat through the ordinary timeline.
None of this requires pretending a test strip is mass spectrometry. Point-of-care testing should be explicitly treated as presumptive. Positive results can be confirmed when necessary. Clinical care rarely rests on a single perfect source of information, anyway.
Further, the value extends beyond the individual patient. Better hospital data could become an early-warning system rather than a retrospective record of a crisis already underway. Emergency departments are on the front lines of the overdose crisis; they should have access to the most innovative testing tools at the bedside, when minutes can make a difference.
Hence then, the article about why doctors are last to know what s in the drug supply was published today ( ) and is available on Time ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Why Doctors Are Last to Know What’s in the Drug Supply )
Also on site :
- In 1957, Ford launched the Edsel after spending $250 million developing it; two years later Ford discontinued it, having lost $350 million
- Steep Height? No Sweat: ‘Everest: The Other Side’s Jim Morrison And Jimmy Chin Repel Down Side Of West Hollywood Building [Video]
- In 1948, William Rosenberg used $1,500 in war bonds and a $1,000 loan to open his first coffee shop; Dunkin’ Donuts later sold for $11.3 billion to Inspire Brand